دورية أكاديمية
Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
| العنوان: | Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial |
|---|---|
| المؤلفون: | Peñalver, Francisco‐Javier, Márquez, Jose‐Antonio, Durán, Soledad, Giraldo, Pilar, Martín, Alejandro, Montalbán, Carlos, López Hernández, Andrés |
| المساهمون: | Peñalver FJ Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain. Márquez JA Hospital de Basurto, Vizcaya, Spain. Durán S Complejo Hospitalario de Jaén, Jaén, Spain. Giraldo P Hospital Universitario Miguel Servet, Zaragoza, Spain. Martín A Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Montalbán C Hospital Universitario Ramón y Cajal, Madrid, Spain. López A Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Wiley Online Library |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Limfomes, Medicaments antineoplàstics, Prognosi, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antineoplastic Combined Chemotherapy Protocols, AND EQUIPMENT::Diagnosis::Prognosis, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma folicular, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, DIAGNÓSTICOS Y TERAPÉUTICOS::Diagnóstico::Pronóstico |
| الوصف: | Bendamustine; Follicular lymphoma; Immunochemotherapy ; Bendamustina; Linfoma folicular; Inmunoquimioterapia ; Bendamustina; Limfoma fol·licular; Immunoquimioteràpia ; Background: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods: This phase II trial evaluated the efficacy and safety of response-adapted therapy with rituximab, bendamustine, mitoxantrone, and dexamethasone (RBMD) in follicular lymphoma patients who relapsed after or were refractory to first-line immunochemotherapy. Sixty patients received three treatment cycles, and depending on their response received an additional one (complete/unconfirmed complete response) or three (partial response) cycles. Patients who responded to induction received rituximab maintenance therapy for 2 years. Results: Thirty-three (55%) and 42 (70%) patients achieved complete/unconfirmed complete response after three cycles and on completing induction therapy (4-6 cycles), respectively (final overall response rate, 88.3%). Median progression-free survival was 56.4 months (median follow-up, 28.3 months; 95% CI, 15.6-51.2). Overall survival was not reached. Progression-free survival did not differ between patients who received four vs six cycles (P = .6665), nor between patients who did/did not receive rituximab maintenance after first-line therapy (P = .5790). Median progression-free survival in the 10 refractory patients was 25.5 months (95% CI, 0.6-N/A) and was longer in patients who had shown progression of disease after 24 months of first-line therapy (median, 56.4 months; 95% CI, 19.8-56.4) than in those who showed early progression (median, 42.31 months; 95% CI, 24.41-NA) (P = .4258). Thirty-six (60%) patients had grade 3/4 neutropenia. Grade 3/4 febrile neutropenia and infection were recorded during induction (4/60 [6.7%] and 5/60 [8.3%] patients, respectively) and maintenance (2/43 [4.5%] and 4/43 [9.1%] patients, respectively). Conclusions: This ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2045-7634 31573746 |
| العلاقة: | Cancer Medicine;8(16); Peñalver FJ, Márquez JA, Durán S, Giraldo P, Martín A, Montalbán C, et al. Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial. Cancer Med. 2019 Nov 1;8(16):6955–66.; https://hdl.handle.net/11351/5127Test; 000488578100001 |
| DOI: | 10.1002/cam4.2555 |
| الإتاحة: | https://doi.org/10.1002/cam4.2555Test https://hdl.handle.net/11351/5127Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F542D648 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20457634 31573746 |
|---|---|
| DOI: | 10.1002/cam4.2555 |